Chronic Disease — Gamifying Patient's Personal Data Validation and Completion in a Personal Health Record
Citation(s)
Cahill JE, Gilbert MR, Armstrong TS Personal health records as portal to the electronic medical record. J Neurooncol. 2014 Mar;117(1):1-6. doi: 10.1007/s11060-013-1333-x. Review.
King D, Greaves F, Exeter C, Darzi A 'Gamification': influencing health behaviours with games. J R Soc Med. 2013 Mar;106(3):76-8. doi: 10.1177/0141076813480996.
McKeown S, Krause C, Shergill M, Siu A, Sweet D Gamification as a strategy to engage and motivate clinicians to improve care. Healthc Manage Forum. 2016 Mar;29(2):67-73. doi: 10.1177/0840470415626528. Review.
Mihaly Csikszentmihalyi 1991. Flow: The psychology of optimal experience. HarperCollins Publishers, New York, New York, USA.
Ryan RM, Deci EL Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol. 2000 Jan;55(1):68-78.
Tang PC, Ash JS, Bates DW, Overhage JM, Sands DZ Personal health records: definitions, benefits, and strategies for overcoming barriers to adoption. J Am Med Inform Assoc. 2006 Mar-Apr;13(2):121-6.
Tang PC, Black W, Young CY Proposed criteria for reimbursing eVisits: content analysis of secure patient messages in a personal health record system. AMIA Annu Symp Proc. 2006:764-8.
Tenforde M, Jain A, Hickner J The value of personal health records for chronic disease management: what do we know? Fam Med. 2011 May;43(5):351-4. Review.
Wells S, Rozenblum R, Park A, Dunn M, Bates DW Organizational strategies for promoting patient and provider uptake of personal health records. J Am Med Inform Assoc. 2015 Jan;22(1):213-22. doi: 10.1136/amiajnl-2014-003055.
Gamifying Patient's Personal Data Validation and Completion in a Personal Health Record
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
